top of page
Search

Epilepsy: Classification & Drug Choice — a Dermatology-Focused Cheatsheet for MRCP Part 1

TL;DR

For MRCP Part 1, epilepsy questions hinge on correct seizure classification → correct first-line drug—with dermatology clues often deciding the mark. Aromatic antiepileptics (carbamazepine, lamotrigine, phenytoin) are high-risk for serious rashes, while valproate dominates generalised epilepsies but carries major restrictions in women of child-bearing potential. Learn the table, spot the skin clues, and avoid classic traps.


Why this matters for MRCP Part 1

Epilepsy is a high-yield topic because it blends neurology fundamentals with pharmacology and adverse effects. In exam stems, dermatological details (rash timing, mucosal involvement, photosensitivity, cosmetic effects) are rarely decorative—they’re the key. This article supports the MRCP Part 1 hub and is designed to pair with question practice and mocks.


Scope & how to use this cheatsheet

  • What you’ll get: seizure classification, drug of choice by seizure type, dermatology-relevant adverse effects, exam traps, and a mini-MCQ.

  • How to revise: memorise the table → drill the rules → test under time pressure.

Seizure classification (exam-first)

Always classify before choosing a drug.

  • Focal onset: aware or impaired awareness; motor or non-motor ± secondary generalisation

  • Generalised onset: tonic-clonic, absence, myoclonic, atonic

  • Unknown onset: uncommon in Part 1

Pearl: Misclassification is the commonest reason for choosing the wrong drug (e.g., carbamazepine worsening absence or myoclonic seizures).


Drug of choice by seizure type (with dermatology hooks)

Seizure type

First-line

Key alternatives

Dermatology-relevant adverse effects / exam notes

Focal onset

Carbamazepine

Lamotrigine, Levetiracetam

Carbamazepine: morbilliform rash; SJS/TEN risk (early weeks). Lamotrigine: rash risk ↑ with rapid titration.

Generalised tonic-clonic

Sodium valproate

Lamotrigine, Levetiracetam

Valproate: alopecia, acne, weight gain; avoid in women of child-bearing potential unless strict criteria met.

Absence

Ethosuximide

Valproate

Ethosuximide: occasional urticaria; carbamazepine worsens absence.

Myoclonic

Sodium valproate

Levetiracetam

Carbamazepine/phenytoin can worsen myoclonus.

Atonic

Sodium valproate

Lamotrigine

As above; watch lamotrigine rash.

Status epilepticus

IV lorazepam (acute)

IV phenytoin/levetiracetam

Phenytoin: purple glove syndrome; chronic gingival hyperplasia.

Memory aid: Generalised → valproate; focal → carbamazepine—unless skin clues say stop.


MRCP Part 1 exam revision setup with medical textbooks and study notes

Dermatology focus: the 5 most tested intersections

  1. Stevens–Johnson syndrome / TEN

    • Highest association: carbamazepine, lamotrigine, phenytoin.

    • Exam action: rash + mucosal involvement → immediate drug cessation and supportive care.

  2. Photosensitivity

    • Seen with carbamazepine and phenytoin (less common). Counsel sun protection.

  3. Alopecia & cosmetic effects

    • Valproate: alopecia, acne, weight gain—often the diagnostic clue.

  4. Gingival hyperplasia

    • Phenytoin classic (chronic use).

  5. Neurocutaneous syndromes

    • Tuberous sclerosis: facial angiofibromas + seizures → multiple seizure types; consider interaction profiles.


High-yield rules (commit to memory)

  1. Classify first; prescribe second.

  2. Carbamazepine = focal; valproate = most generalised.

  3. Absence → ethosuximide (not carbamazepine).

  4. Myoclonic seizures worsen with carbamazepine/phenytoin.

  5. Rash with mucosal involvement = stop the drug now.

  6. Lamotrigine rash risk rises with fast titration or valproate co-use.

  7. Avoid valproate in women of child-bearing potential unless no alternative.

  8. Status: benzodiazepine first, then a longer-acting agent.


Mini-MCQ (with explanation)

Stem: A 24-year-old woman has brief staring spells with eyelid fluttering precipitated by hyperventilation. EEG shows 3-Hz spike-and-wave discharges. Best first-line treatment?

A. CarbamazepineB. PhenytoinC. EthosuximideD. LamotrigineE. Levetiracetam

Answer: C — Ethosuximide. Why: Classic absence epilepsy. Carbamazepine and phenytoin worsen absence seizures. Lamotrigine is an alternative but not first-line.


Common pitfalls (5)

  • Treating absence epilepsy with carbamazepine.

  • Missing early-onset rashes with aromatic antiepileptics.

  • Forgetting valproate restrictions in women of child-bearing potential.

  • Rapid lamotrigine titration leading to rash.

  • Overlooking enzyme induction and drug interactions affecting skin therapies or contraception.


Practical study-tip checklist

  • ☐ Write the seizure classification before scanning options.

  • ☐ Circle skin clues (rash timing, mucosa, photosensitivity, cosmetic effects).

  • ☐ Apply first-line rules, then exclude contraindications.

  • ☐ Rehearse the status epilepticus sequence.

  • ☐ Finish with timed blocks from the Qbank and a full mock.


FAQs

Which antiepileptic drugs most commonly cause serious skin reactions?Aromatic agents—carbamazepine, lamotrigine, and phenytoin—especially early after initiation.

What is first-line for absence seizures in MRCP Part 1?Ethosuximide. Carbamazepine and phenytoin can worsen absence seizures.

Why is valproate often avoided in women of child-bearing potential?

Because of significant teratogenic and neurodevelopmental risks; use only if no suitable alternatives with strict safeguards.

Which drug causes gingival hyperplasia?

Phenytoin, classically with chronic use.


Ready to start?

Lock this down with practice: run a timed set on the Qbank (https://www.crackmedicine.com/qbank/) and then start a mock test (https://www.crackmedicine.com/mock-tests/). For structured revision, explore lectures and notes from the MRCP Part 1 hub (https://www.crackmedicine.com/mrcp-part-1/).


Sources

 
 
 

Comments

bottom of page